These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34064515)

  • 1. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
    Shima Y
    Cells; 2021 May; 10(5):. PubMed ID: 34064515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.
    Shima Y
    Mod Rheumatol; 2019 Mar; 29(2):294-301. PubMed ID: 30561237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement.
    De Luca G; Cavalli G; Campochiaro C; Bruni C; Tomelleri A; Dagna L; Matucci-Cerinic M
    Front Immunol; 2021; 12():653950. PubMed ID: 33833766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis.
    Gasparini G; Cozzani E; Parodi A
    Cytokine; 2020 Jan; 125():154799. PubMed ID: 31400638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
    Taniguchi T; Asano Y; Fukasawa T; Yoshizaki A; Sato S
    J Dermatol; 2017 Aug; 44(8):967-971. PubMed ID: 28342234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis.
    MacDonald KG; Dawson NAJ; Huang Q; Dunne JV; Levings MK; Broady R
    J Allergy Clin Immunol; 2015 Apr; 135(4):946-955.e9. PubMed ID: 25678090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
    Zacay G; Levy Y
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
    Sakkas LI
    Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Alarmins in the Pathogenesis of Systemic Sclerosis.
    Giovannetti A; Straface E; Rosato E; Casciaro M; Pioggia G; Gangemi S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
    Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
    Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of scleroderma. Collagen.
    Jimenez SA; Hitraya E; Varga J
    Rheum Dis Clin North Am; 1996 Nov; 22(4):647-74. PubMed ID: 8923589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis.
    Manetti M; Ibba-Manneschi L; Liakouli V; Guiducci S; Milia AF; Benelli G; Marrelli A; Conforti ML; Romano E; Giacomelli R; Matucci-Cerinic M; Cipriani P
    Ann Rheum Dis; 2010 Mar; 69(3):598-605. PubMed ID: 19778913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in the pathogenesis of systemic sclerosis.
    Sakkas LI
    Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The
    Kavian N; Mehlal S; Jeljeli M; Saidu NEB; Nicco C; Cerles O; Chouzenoux S; Cauvet A; Camus C; Ait-Djoudi M; Chéreau C; Kerdine-Römer S; Allanore Y; Batteux F
    Front Immunol; 2018; 9():1896. PubMed ID: 30177933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress in the pathogenesis of systemic scleroderma: An overview.
    Vona R; Giovannetti A; Gambardella L; Malorni W; Pietraforte D; Straface E
    J Cell Mol Med; 2018 Jul; 22(7):3308-3314. PubMed ID: 29664231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of CD8+ T cells to inflammatory cytokine production in systemic sclerosis (SSc).
    Klein M; Schmalzing M; Almanzar G; Benoit S; Hamm H; Tony HP; Goebeler M; Prelog M
    Autoimmunity; 2016 Dec; 49(8):532-546. PubMed ID: 27560622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
    Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
    Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.